Article info

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Authors

  1. Correspondence to Dr David Gold, Pfizer Inc, Montreal, QC H9J 2M5, Canada; David.Gold{at}pfizer.com
View Full Text

Citation

Winthrop KL, Citera G, Gold D, et al
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Publication history

  • Received August 28, 2020
  • Revised September 16, 2020
  • Accepted September 16, 2020
  • First published October 12, 2020.
Online issue publication 
December 14, 2020

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.